Small cell lung cancer extensive stage

34 trials 11 recruiting MedDRA PT
34 Registered trials
11 Recruiting
22 Unique sponsors
34 Unique IMPs
27 Commercial trials
Drug classes (ATC)
— ATC code not specified 20
L Oncology (ATC L) 14
B Haematology (ATC B) 1
N Neurology/Psychiatry (ATC N) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 15 substances
Checkpoint inhibitor (PD-L1) 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Antibody-drug conjugate (ADC) 2 substances
PARP inhibitor 2 substances
Platinum compound 2 substances
Monoclonal antibody (rat) 1 substance
Monoclonal antibody (human) 1 substance
Topoisomerase I inhibitor 1 substance
Supportive / diluent 1 substance
CDK inhibitor 1 substance
Kinase inhibitor 1 substance
Radiopharmaceutical 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Topoisomerase II inhibitor 1 substance
Phase III: 8 Phase II/III: 1 Phase II: 11 Phase I/II: 4 Phase I: 1 Phase I (Other): 7 Phase I (First in Human): 2

Filter these 34 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 34 trials

Phase III

8 trials
  • Amgen Inc. Commercial
    TARLATAMAB
    2023-505989-29-00 16 countries 2024 n=318 Orphan
    Ended
  • Amgen Inc. Commercial
    TARLATAMAB
    2024-520050-38-00 13 countries 2025 n=129 Orphan
    Ended
  • BioNTech SE Commercial
    ATEZOLIZUMAB; BNT327
    2024-515765-34-00 7 countries 2026 n=249
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    NIVOLUMAB, ATIGOTATUG
    2024-515740-23-00 11 countries 2025 n=212
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; TIRAGOLUMAB
    2022-502988-37-00 3 countries 2020 n=90
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; LURBINECTEDIN
    2023-503868-16-00 7 countries 2022 n=332
    Ended
  • Gilead Sciences Inc. Commercial
    SACITUZUMAB GOVITECAN; TOPOTECAN
    2024-515884-69-00 11 countries 2025 n=254
    Recruiting
  • Pharmacosmos A/S Commercial
    SODIUM CHLORIDE; TOPOTECAN; TRILACICLIB DIHYDROCHLORIDE DIHYDRATE
    2022-502357-34-00 8 countries 2023 n=250
    Recruiting

Phase II/III

1 trial

Phase II

11 trials
  • AstraZeneca AB Commercial
    DEFOSBARASERTIB; DURVALUMAB
    2024-511887-10-00 1 country 2021 n=3
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    [89ZR]BMS-986279; HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST FUCOSYL-GM1; NIVOLUMAB
    2024-510700-36-00 7 countries 2021 n=135
    Ended
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2024-512368-79-00 3 countries 2022 n=49
    Ended
  • Owlstone Medical Limited Commercial
    D5-ETHYL-BETA-D-GLUCURONIDE
    2023-503574-20-00 2 countries 2023 n=100
    Ended
  • AIO-Studien gGmbH Academic
    TARLATAMAB
    2025-522437-65-00 1 country 2026 n=57
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    ATEZOLIZUMAB; DURVALUMAB; NIRAPARIB TOSILATE MONOHYDRATE
    2022-502092-33-00 5 countries 2024 n=35 Orphan
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    TARLATAMAB
    2025-522288-13-00 4 countries n=40
    Pending
  • Fundacion GECP Academic
    LENVATINIB; PEMBROLIZUMAB
    2024-511412-25-00 1 country 2022 n=46
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    DURVALUMAB
    2023-504670-38-00 2 countries 2023 n=72
    Recruiting
  • Universitaet Des Saarlandes Academic
    CARBOPLATIN; CISPLATIN; DURVALUMAB; ETOPOSIDE
    2024-517937-41-00 1 country n=43
    Pending
  • University Of Cologne Academic
    DURVALUMAB; OLAPARIB
    2024-512373-27-00 1 country 2024 n=29
    Recruiting

Phase I/II

4 trials
  • Bristol Myers Squibb International Corporation Commercial
    HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST FUCOSYL-GM1
    2024-511824-15-00 1 country 2016 n=1
    Ended
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509629-36-00 2 countries 2025 n=48
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    LENVATINIB; MK-4830; PEMBROLIZUMAB; PEMBROLIZUMAB, FAVEZELIMAB; PEMBROLIZUMAB, QUAVONLIMAB; RALUDOTATUG DERUXTECAN
    2023-507687-38-00 5 countries 2021 n=59
    Ended
  • Novartis Pharma AG Commercial
    ARGININE HYDROCHLORIDE, LYSINE HYDROCHLORIDE; DOTATATE; LUTETIUM (177LU) OXODOTREOTIDE; TISLELIZUMAB
    2024-513185-19-00 8 countries 2022 n=86 Orphan
    Recruiting

Phase I

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2023-506541-39-00 6 countries 2018 n=118
    Ended

Phase I (Other)

7 trials
  • Amgen Inc. Commercial
    IMP not specified
    2024-511021-58-00 6 countries 2022 n=80
    Ended
  • Amgen Inc. Commercial
    IMP not specified
    2024-511838-12-00 4 countries 2024 n=86
    Recruiting
  • Amgen Inc. Commercial
    IMP not specified
    2024-515903-21-00 6 countries 2025 n=47
    Halted
  • Amgen Inc. Commercial
    IMP not specified
    2025-522888-15-00 5 countries 2026 n=53
    Recruiting
  • Boehringer Ingelheim International GmbH Commercial
    IMP not specified
    2023-506007-26-00 3 countries 2024 n=71
    Ended
  • Boehringer Ingelheim International GmbH Commercial
    IMP not specified
    2023-506008-20-00 5 countries 2024 n=40
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2023-509800-14-00 2 countries 2019 n=66
    Ended

Phase I (First in Human)

2 trials
  • Fortvita Biologics (USA) Inc. Commercial
    IMP not specified
    2025-523972-21-00 3 countries n=30
    Pending
  • Novartis Pharma AG Commercial
    DJI136
    2025-523276-23-00 2 countries n=25
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 7 Phase I, Phase I (Other), Phase III 2
Boehringer Ingelheim International GmbH Commercial 2 Phase I (Other) 0
Bristol Myers Squibb International Corporation Commercial 2 Phase II, Phase I/II 0
Daiichi Sankyo Inc. Commercial 2 Phase II, Phase I/II 1
F. Hoffmann-La Roche AG Commercial 2 Phase III 0
Novartis Pharma AG Commercial 2 Phase I (First in Human), Phase I/II 1
ETOP IBCSG Partners Foundation Academic 2 Phase II 1
Pfizer Inc. Commercial 1 Phase II/III 0
Celgene Corp. Commercial 1 Phase I (Other) 0
AstraZeneca AB Commercial 1 Phase II 0
Owlstone Medical Limited Commercial 1 Phase II 0
BioNTech SE Commercial 1 Phase III 1
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 0
Gilead Sciences Inc. Commercial 1 Phase III 1
Pharmacosmos A/S Commercial 1 Phase III 1
Fortvita Biologics (USA) Inc. Commercial 1 Phase I (First in Human) 0
Merck Sharp & Dohme LLC Commercial 1 Phase I/II 0
AIO-Studien gGmbH Academic 1 Phase II 1
Fundacion GECP Academic 1 Phase II 0
Intergroupe Francophone De Cancerologie Thoracique Academic 1 Phase II 1
New trials by year
2019
1
2020
1
2021
3
2022
5
2023
3
2024
6
2025
5
2026
3
← All indication landscapes